Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

In vivo CAR-T therapy transforms customized treatments into universal medicines (opens in a new tab)

news-medical.net · 2026-09-25

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 8Not checkedThe article says in vivo CAR-T transfers the T-cell engineering process into the patient's body, which could reduce time and cost from weeks of manufacturing to practically immediate availability.View evidenceHide evidence

As statedfrom weeks of manufacturing to practically immediate availability

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 8Not checkedA collaborative team led by Professor Huji Xu, together with Professors Xuanming Yang and Yujia Cai, published a comprehensive review in Immunity & Inflammation on August 31, 2026.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 8Not checkedThe authors point out that early clinical translation is accelerating, and say that LNP-mRNA and targeted lentiviral systems have achieved efficient T cell transduction and deep target cell clearance in non-human primate models, while early-phase clinical trials for relapsed/refractory multiple myeloma and autoimmune diseases have shown promising safety and preliminary efficacy.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 8Not checkedThe review systematically summarizes the development history, key engineering strategies, and clinical translation progress of in vivo chimeric antigen receptor T cells (CAR-T) technology.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 8Not checkedIt states that in vivo transduction may keep T cells in a more native, undifferentiated state such as memory stem cells, potentially improving self-renewal and anti-tumor persistence.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 8Not checkedThe review describes viral vector platforms, including targeted lentiviral vectors and engineered adeno-associated viruses, as well as non-viral platforms such as lipid nanoparticles, polymeric nanoparticles, and virus-like particles.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 7 of 8Not checkedThe review highlights challenges including persistence limitations, off-target and on-target toxicity, immunogenicity, repeat administration, and exhausted patient T cells, and it discusses solutions such as circular RNA, self-amplifying RNA, logic-gated dual-recognition strategies, T cell-specific promoters, stealth vector design, transient immunomodulation, cytokine pre-treatment, and anti-exhaustion genes.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 8 of 8Not checkedThe article concludes that in vivo CAR-T may mature into a reliable off-the-shelf genetic medicine with potential applications in cancer, autoimmune diseases, and beyond.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

In vivo CAR‑T therapy: recent progress and future directions

Immunity & Inflammation · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

MM-561: Dual-Target CAR-T and in Vivo Platforms in Relapsed/Refractory Multiple Myeloma: A Systematic Scoping Review of Efficacy, Toxicity, and Access

Clinical Lymphoma Myeloma and Leukemia · 2026 · Crossref

Source (opens in a new tab)
Candidate

CT-989: Clinical Outcomes and Safety Profile of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Clinical Lymphoma Myeloma and Leukemia · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.